Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $750.00 by Analysts at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by Citigroup from $795.00 to $750.00 in a research report released on Tuesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Price Performance

REGN opened at $686.33 on Tuesday. The firm has a 50-day moving average price of $725.65 and a 200-day moving average price of $933.22. Regeneron Pharmaceuticals has a twelve month low of $666.25 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $75.42 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 1.59 and a beta of 0.10.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in REGN. International Assets Investment Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $127,489,000. KBC Group NV increased its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares during the period. Icon Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the last quarter. Finally, State Street Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.